Securing Critical Quality Attributes (CQA) of CGT Products with Strong In-House Cryo Cold Chain Management
Part 1 of a three-part series on cryo cold chain management for cell and gene therapies With a projected rate of 10-20 product approvals per year, the global cell and gene therapy (CGT) industry is rapidly evolving. The clinical pipeline delivers a promise to the patient population with unmet medical needs ranging from oncology to […]
View Blog